Pacific Shores Medical Group
Phone:    562-590-0345
​Toll Free: 855-590-0345
  • Home
  • Our Physicians
  • Our NPs and PAs
  • Research Program
  • Hospital Affiliations
  • Insurance Plans
  • Office Locations
    • Glendale
    • Huntington Beach
    • Irvine
    • Long Beach Elm
    • Long Beach Worsham
    • Newport Beach
  • Office Information
    • Office Brochures
    • Espanol
    • Chinese
  • New Patient Information
  • PET Scan
  • Resources
  • Blog
  • Patient Portal

Idelalisib Research Program Open for Lymphoma

4/23/2013

 
Dr. Andre K.D. Liem, MDAndre K.D. Liem, MD
Idelalisib (eye-del-a-lis-ib) (GS 1101, GS-1101) (formerly CAL-101) is an oral inhibitor of PI3K-delta. The PI3K pathway is an important for many cellular functions such as growth control. PI3K delta is critical for activation, proliferation and survival of B lymphocytes. In many B cell malignancies the PI3K signalling is hyperactive causing increased proliferation, survival and trafficking to lymphoid tissue. Idelalisib has shown to inhibit proliferation and induce apoptosis (cell death) in many B cell malignancies in pre-clinical and clinical studies.

We have opened two clinical trials for indolent lymphoma:
  1. Rituximab with or without Idelalisib: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (for more info see clinicaltrials.gov click here)
  2. Rituximab and bendamustine with or without Idelalisib: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (for more info see clinicaltrials.gov click here)


This target group is patient with low grade lymphoma who have received treatment with rituximab (with or without chemotherapy, but have a recurrence. Both studies have  three treatment arms. Two arms have contain idelalisib and on arm has placebo. Everybody will get treatment with rituximab or rituxumab and bendamustine depending on the study.

These research trials are open at our Long Beach (Elm and Worsham), Huntington Beach and Irvine locations.

For more information call Irene at 562-590-0345

    News From PSMG

    The latest news at Pacific Shores Medical Group

    Archives

    December 2018
    June 2018
    May 2018
    August 2017
    July 2017
    June 2017
    March 2014
    November 2013
    August 2013
    April 2013
    March 2013
    January 2013

    Categories

    All
    Breast Cancer
    Immunotherapy
    Lung Cancer
    Lymphoma
    Multiple Myeloma
    Prostate Cancer

    RSS Feed

    Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.
Home    Disclaimer   Contact Us
Office Locations -  Glendale  -  Huntington Beach  -  Irvine  -  Long Beach Elm  -  Long Beach Worsham - Newport Beach -
© 2018 Pacific Shores Medical Group